A team of researchers has now pushed the frontier of battery science by engineering a novel BiOCl/Bi heterostructure that self-assembles on the zinc anode surface, providing remarkable protection and regulation. This advanced interface introduces a synergistic interplay between ion transport and an intrinsic electric field, a dual-action system that addresses the root causes of anode degradation. Central to its design is the fabrication of a Bi/BiOCl protective layer, which not only acts as a physical barrier but also plays an active role in modulating zinc ion deposition kinetics and suppressing parasitic reactions. The careful orchestration of these factors achieves a transformational leap in battery durability and reliability.

At the heart of this breakthrough lies the establishment of a bidirectional ion-electric field coupling. The BiOCl component forms an intimate heterostructure with metallic bismuth (Bi), generating an internal electric field that exerts directional control over zinc ions. This field acts as a dynamic shield, ensuring uniform zinc ion flux and deposition across the anode surface. Preventing localized ion concentration gradients mitigates the nucleation and growth of zinc dendrites—needle-like metallic protrusions that penetrate the separator, causing internal short circuits and eventual cell failure. The electric field’s role as an active guiding force signifies a new paradigm in battery interfaces, where the anode surface becomes an intelligent participant in electrochemical processes.

Complementing the electric field-induced regulation, the metallic Bi sites embedded within the heterostructure serve as potent nucleation centers for zinc ion reduction. These Bi sites exhibit strong affinity for zinc ions, effectively lowering the activation energy barrier for Zn plating and stripping reactions. This catalytic effect enhances the overall reversibility and kinetics of the electrodeposition process, leading to faster charging and discharging rates with minimal energy loss. By combining these two mechanisms—electric field guidance and catalytic seeding—the system achieves a meticulously balanced interface that sustains high performance under diverse and demanding operational environments.

Experimental validation underscores the robustness of this engineered anode. The batteries constructed with the BiOCl/Bi heterostructured zinc anode could endure over 2,500 hours of continuous cycling under strenuous test conditions without significant capacity degradation. More impressively, these batteries demonstrated stability across an exceptionally broad temperature range, maintaining performance from the icy depths of -20 °C to the blistering heat of 70 °C. This thermal tolerance marks a critical advancement toward practical applications where batteries must reliably operate in fluctuating environmental conditions without compromising safety or efficiency.

The implications of these findings are profound for energy infrastructure on a global scale. Massive energy storage systems—critical for buffering renewable energy sources like solar and wind—require batteries that combine affordability, safety, and endurance. By resolving the zinc anode’s intrinsic limitations, this BiOCl/Bi heterostructure paves the way for AZIBs to fulfill their promise as safe, scalable, and cost-effective solutions. Furthermore, the long cycling life verified by hybrid capacitor prototypes exceeding 15,000 cycles suggests adaptability of the technology beyond traditional battery formats, encompassing fast-response energy storage devices.

From a materials science perspective, the self-forming nature of the Bi/BiOCl protective layer represents a pragmatic advantage in manufacturing. Unlike complex coating procedures often needed in battery electrode fabrication, the in situ growth mechanism simplifies production, reduces costs, and enhances compositional uniformity. This scalability is essential for transitioning laboratory breakthroughs into commercial viability, promoting faster integration into the energy storage market.

The integration of this heterostructure also addresses long-standing parasitic reactions that plague zinc anodes, such as hydrogen evolution. By establishing an energetic barrier, the BiOCl layer inhibits unwanted side reactions that consume electrolyte and active material, which could otherwise lead to swelling, gas buildup, and loss of capacity. This chemical stability enhances the overall safety profile, making these batteries more dependable in real-world conditions, including extreme thermal environments.

Looking ahead, the principle of bidirectional ion-electric field synergy opens intriguing avenues for future battery design. Extending this approach to other aqueous and solid-state battery chemistries could yield similar enhancements in ion transport control and electrode stability. The conceptual advance also invites further exploration into heterostructured interfaces combining layered materials and metals to tailor electrochemical properties with high precision.

In summary, the advent of the BiOCl/Bi heterostructured zinc anode constitutes a landmark innovation in aqueous zinc-ion battery technology. By harmonizing electric field-driven ion guidance and catalytic nucleation, this dual-action strategy robustly overcomes the critical limitations of dendrite formation and side reactions while delivering exceptional longevity and thermal adaptability. This development not only revitalizes the prospects of AZIBs for grid-level energy storage but also signals a broader shift toward intelligent electrode interface engineering as a foundation for next-generation rechargeable batteries. As global energy demands intensify and sustainability becomes paramount, breakthroughs like this will be pivotal in realizing a resilient and clean energy future.

Subject of Research: Aqueous zinc-ion batteries (AZIBs) and zinc anode stabilization via BiOCl/Bi heterostructure

Article Title: Bidirectional Ion–Electric Field Synergy via In Situ Grown BiOCl/Bi Heterostructure Enabling Ultra–Stable Zinc Anodes Across Wide Temperatures

Web References: DOI: 10.1016/j.scib.2025.10.004

References: Science Bulletin journal article published by Science China Press

Image Credits: ©Science China Press

Keywords

Aqueous zinc-ion battery; zinc anode; BiOCl/Bi heterostructure; dendrite suppression; ion-electric field synergy; in situ growth; zinc plating; electrode stability; battery cycling life; thermal stability; parasitic reaction inhibition; energy storage technology

At the heart of this study is the prodrug SN38, a potent active metabolite of the well-known chemotherapy agent Irinotecan. SN38 has been shown to possess remarkable anticancer properties, but its clinical application has been severely limited by solubility and systemic toxicity issues. By harnessing the power of nano-assemblies, researchers have found a way to improve the stability and bioavailability of SN38, thereby enhancing its therapeutic efficacy while minimizing adverse effects. This offers a promising avenue for enhanced drug delivery strategies that aim at maximizing the potential of established chemotherapeutics.

The innovative aspect of this research lies in the dual character of surface engineering applied to the SN38 prodrug nano-assemblies. By manipulating the surface properties of these nanoparticles, the research team was able to tailor their interactions with biological environments uniquely. This customization plays a crucial role in determining how the drug is released, how it is absorbed by the target tissues, and how effectively it can exert its anticancer effects.

One of the standout features of the study was the emphasis on the differential behaviors of the engineered nano-assemblies in in vitro and in vivo settings. In vitro studies revealed that the surface modifications significantly impacted cellular uptake rates, leading to enhanced efficacy in tumor cell lines. The nanoparticles demonstrated a swift interaction profile with cancer cells, allowing for higher concentrations of SN38 delivery directly where it is most needed. This marked improvement in cellular uptake not only underpins the potential for increased treatment efficacy but also sets a precedent for future research in this area.

The in vivo studies took the findings a step further by employing animal models, providing crucial insights into the pharmacokinetics and biodistribution of the nano-assemblies. Remarkably, the researchers found that the surface-engineered nano-assemblies exhibited a higher accumulation of SN38 in tumor tissues compared to their unmodified counterparts. This notable finding underscores the importance of surface engineering in developing more targeted cancer therapies, enabling higher doses to reach malignant tissues while sparing healthy cells.

Moreover, the study emphasized the influence of surface charge and hydrophilicity on the behavior of the SN38 prodrug nano-assemblies. These factors play a pivotal role in determining how the nanoparticles interact with biological barriers, including cell membranes and vascular endothelial cells. For instance, positively charged particles showed increased interaction rates with negatively charged cell membranes, facilitating enhanced cellular internalization. Conversely, the hydrophilicity of the surface modifications dictated the dispersion of the nanoparticles in biological fluids, impacting their circulation time and distribution throughout the body.

The implications of these findings extend beyond mere efficacy. The dual character of surface engineering may also hold promise in addressing the long-standing challenge of drug resistance, particularly in cancer therapies, by ensuring that higher concentrations of the drug can be delivered directly to resistant cell populations. By circumventing classical mechanisms of drug resistance, engineered nanoparticles could offer a novel strategy to enhance the effectiveness of chemotherapy, potentially leading to better patient outcomes.

Furthermore, the research team plans to explore the possibilities of this technology in combination therapies, where SN38 could be used alongside other agents to trigger synergistic effects. Such strategic combinations could hold the key to overcoming resistance mechanisms, amplifying the total therapeutic impact of cancer treatment regimens.

Another pivotal element of this research is its contribution to personalized medicine. The ability to engineer and modify nanoparticles to fit specific patient profiles marks a radical shift towards customized treatment protocols. By tailoring the surface features of nano-assemblies to match the unique biological environment of individual tumors, researchers could optimize drug delivery on a case-by-case basis. This highly personalized approach opens the door to more effective and less toxic interventions.

The publication of these findings in “Military Medical Research” comes at a crucial time in the fight against cancer, as newer therapeutic approaches are desperately needed in the clinical landscape. The quest to improve drug delivery systems has garnered tremendous interest over the years, and this research embodies the cutting-edge advances in nanomedicine. It raises the bar for future studies that seek to explore the interplay between surface modifications and therapeutic outcomes.

The insights gained from the research have set a foundation for future investigations. The scientific community is optimistic that these nano-assemblies can serve as a blueprint for developing more effective drug delivery systems across various therapeutic areas, not limited to oncology. With ongoing advancements in nanotechnology and biopharmaceuticals, the horizon looks promising for achieving more targeted and effective treatments for a myriad of diseases.

Looking ahead, the research will undoubtedly inspire further exploration into the dual nature of surface engineering. Scientists will continue to investigate the underlying mechanisms that govern the interactions between engineered nanoparticles and biological systems, with the ultimate goal of translating these findings into clinical practice. As this field evolves, the potential for enhanced patient care through innovative drug delivery systems is becoming increasingly apparent. Exciting times lie ahead in the realm of nanomedicine, as researchers strive to unlock the full potential of engineered nanoparticles in transforming therapeutic landscapes.

In conclusion, the dual character of surface engineering on SN38 prodrug nano-assemblies represents a promising breakthrough in the pharmacological sciences. By elucidating the divergent effects observed in vitro and in vivo, this research not only addresses current challenges in drug delivery but also heralds a new era of tailored cancer therapies. Given the rise of personalized medicine and the necessity for innovative solutions, the future of this field may very well pivot on the successes of such pioneering studies, paving the way for more effective and less toxic cancer treatments.

Subject of Research: Dual character of surface engineering on SN38 prodrug nano-assemblies.

Article Title: Dual character of surface engineering on SN38 prodrug nano-assemblies: divergent effects on in vitro and in vivo behavior.

Article References:

Li, YQ., Kuang, ZY., Zhang, BY. et al. Dual character of surface engineering on SN38 prodrug nano-assemblies: divergent effects on in vitro and in vivo behavior.
Military Med Res 12, 60 (2025). https://doi.org/10.1186/s40779-025-00648-6

Image Credits: AI Generated

DOI: 10.1186/s40779-025-00648-6

Keywords: SN38, prodrug, nano-assemblies, surface engineering, drug delivery, cancer therapy, personalized medicine, in vitro, in vivo.